Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler
Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that it has received an order from a company revenue wise ranking among the top ten largest pharma companies in the world to evaluate a multi-dose inhaler from Iconovo. The study is a so-called in-vitro study to assess the suitability of using the inhaler in the development of an originator medicine. The order value is 220 000 SEK and is to be performed during next three months. The order value is limited but may lead to further collaboration if the evaluation concludes positive.
Iconovo rekryterar Gary Pitcairn (PhD) som Senior Scientific Advisor
Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, meddelar idag att Gary Pitcairn kommer att börja arbeta för bolaget i rollen som Senior Scientific Advisor. Gary är en erkänd expert inom utveckling av läkemedelsberedningar för inhalation, och är ordförande i den vetenskapliga organisationskommittén för den årliga internationella konferensen Drug Delivery to the Lungs (DDL).
Iconovo recruits Gary Pitcairn (PhD) as Senior Scientific Advisor
Iconovo AB (publ), which develops complete inhalation products for a global market, announce today that Gary Pitcairn will start working for the company in the role as Senior Scientific Advisor. Gary is a recognised expert in inhaled drug delivery and currently acts as the chairman of the Scientific Organising Committee of the annual Drug Delivery to the Lungs (DDL) international conference.
Iconovo AB changes liquidity provider and Certified Adviser to Carnegie Investment Bank AB (publ)
Iconovo AB announces today that it is changing liquidity provider and Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).
Iconovo AB byter likviditetsgarant och Certified Adviser till Carnegie Investment Bank AB (publ)
Iconovo AB meddelar idag att man byter likviditetsgarant och Certified Adviser från Erik Penser Bank AB till Carnegie Investment Bank AB (publ).
Nomination Committee appointed at Iconovo AB
At the Annual General Meeting of 17 May 2022, it was resolved that Iconovo AB shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September each year.
Valberedning utsedd Iconovo AB
Vid årsstämman den 17 maj 2022 beslutades att Iconovo AB ska ha en valberedning som ska bestå av fyra ledamöter representerande de fyra största aktieägarna per den siste september varje år.
Iconovo och Arcede Pharma tar nästa steg i utvecklingen av en ny behandling mot KOL
Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, och Arcede Pharma, som utvecklar inhalationsbehandlingar mot KOL och svår astma, meddelar idag att samarbetsprojektet kring Arcedes läkemedelskandidat RCD405 fortskrider med goda resultat. Nästa steg i projektet, är en teknisk stabilitetsstudie innan substansen kan testas kliniskt.
Iconovo and Arcede Pharma take the next step in the development of a new treatment for COPD
Iconovo AB (publ), which develops complete inhalation products for a global market, and Arcede Pharma, which develops inhalation treatments for COPD and severe asthma, announce today that the collaborative project around Arcede's drug candidate RCD405 is progressing with good results. The next step in the project is a technical stability study before the drug candidate can be tested clinically.
Iconovos styrelseledamot och medgrundare Mats Johansson förvärvar aktier för 2 039 388 SEK
Iconovo AB (publ) meddelar idag att Mats Johansson, styrelseledamot och medgrundare, har förvärvat 163 151 aktier för totalt 2 039 388 SEK. Förvärvet genomfördes den 27 oktober som en villkorad del av den nyemission som annonserades den 26 september och skedde genom bolaget Abraxas Holding AB.
